NIAID-funded study could offset harsh effects of antibiotics.
Researchers at Memorial Sloan Kettering Cancer Center have shown that autologous fecal microbiota transplantation (auto-FMT) is a safe and effective way to help replenish beneficial gut bacteria in cancer patients who require intense antibiotics during allogenic hematopoietic stem cell transplantation. In their study, patients who underwent the procedure were randomly assigned into two groups: one group received standard care and the other received auto-FMT. The researchers found that auto-FMT resulted in the recovery of beneficial gut bacteria to near baseline levels within days, thus restoring patients’ digestive, immune and other essential functions. With standard care, beneficial bacteria typically take many weeks to recover from antibiotic treatment, leaving patients at risk of other infectious diseases, including Clostridium difficile.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, provided funding for part of the project. The study report appears in Science Translational Medicine.
“This important study suggests that clinical intervention using auto-FMT can safely reverse the disruptive effects of broad-spectrum antibiotic treatment,” says NIAID Director Anthony S. Fauci, M.D. “If validated in larger studies, this approach may prove to be a relatively simple way to quickly restore a person’s healthy microbiome following intensive antimicrobial therapy.”
Allogenic hematopoietic cell transplantation involves a donor — often but not exclusively a family member — who gives the recipient stem cells that re-establish bone marrow production of blood cells and immune function to combat cancer. Antibiotics are essential to prevent bacterial infections in stem cell recipients. However, antibiotics also destroy beneficial bacteria that enhance immune function and resistance to infection. The loss of beneficial bacteria increases the risk of certain life-threatening infectious diseases and graft-versus-host disease (GVHD).
The study involved cancer patients who provided their own fecal sample, which was frozen and stored prior to their cell transplantation procedure. Weeks later, when physicians confirmed that the transplanted cells were growing, they assessed the status of the patients’ beneficial gut bacteria. The first 25 patients who lacked known beneficial bacteria were enrolled into the study and randomly assigned to the different treatment groups: 14 received auto-FMT by enema and 11 received standard-of-care.
The patients who received auto-FMT consistently regained bacterial diversity, composition and function; recovery of beneficial bacteria in the 11 control patients was delayed.
The researchers are continuing to monitor the study patients to determine if auto-FMT improves patient outcomes, such as the incidence and severity of bacterial, viral and fungal infections and the incidence and severity of GVHD. Whether FMT from a healthy donor would be as beneficial as the patient’s own fecal sample at restoring beneficial bacteria remains to be studied.
The Latest on: Fecal microbiota transplantation
[google_news title=”” keyword=”fecal microbiota transplantation” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Fecal microbiota transplantation
- C.diff guidelines revised for patients with recurrent infectionson February 22, 2024 at 12:43 pm
For individuals who continue to experience recurrent C.diff infections, the group recommends the traditional practice of treatment: fecal microbiota transplants (FMT). The above transplantation method ...
- New guidelines recommend fecal microbiota transplant, related therapies for most patients with recurrent C diffon February 21, 2024 at 12:30 pm
In mildly or moderately immunocompromised adults with recurrent CDI, the AGA recommends select use of conventional FMT upon completion of antibiotics. But severely immunocompromised adults with ...
- AGA guideline endorses fecal microbiota transplant as treatment for recurrent C. diff infectionon February 21, 2024 at 7:42 am
In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends fecal ...
- Fecal Transplant Therapies Recommended for Recurrent C. difficile in Some Patientson February 21, 2024 at 6:53 am
In C. difficile patients, fecal microbiota-based therapies may be considered by a patient when C. difficile infections no longer respond to antibiotics within 2 to 5 days of treatment or after the ...
- Guideline now recommends fecal microbiota transplant for the majority of recurrent C. diff patientson February 21, 2024 at 1:00 am
the American Gastroenterological Association recommends fecal microbiota transplant (FMT) for most patients with recurrent Clostridioides difficile (C. diff) infection. "Using fecal microbiota ...
- AGA Backs Fecal Microbiota-Based Therapies for Recurrent C. Diffon February 20, 2024 at 4:00 pm
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The American Gastroenterological Association (AGA) endorsed ...
- COPD improved by tweaks to microbiome via fecal transplant or dieton February 15, 2024 at 9:08 pm
Improving the health of the gut microbiome by way of fecal transplant (in mice) and dietary modification (in humans), has been shown by researchers to noticeably improve COPD symptoms. The finding ...
- Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantationon February 14, 2024 at 4:00 pm
The microbiota composition of fecal samples obtained from patients who were undergoing allogeneic hematopoietic-cell transplantation at four centers was profiled by means of 16S ribosomal RNA gene ...
- Fecal microbiota transplants: Past, present and futureon February 9, 2024 at 11:16 am
The premise of fecal microbiota transplants (FMT) is, admittedly, not the most pleasant. The process involves transferring donor stool (or derivatives thereof) to a recipient for a therapeutic purpose ...
via Bing News